VALEANT PROFITS UP 34%

Bausch & Lomb Inc.’s new owner, Valeant Pharmaceuticals Incorporated, the new owner of Bausch and Lomb, reported a second quarter profit on revenues that were up by 34 percent.
Valeant reported net income of $10.9 million, or 3 cents a dilute share this year, compared with a loss of $21.6 million, or 7 cents a share during the same period last year.
Valeant’s total revenues were $1.1 billion.

Leave a Reply